Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Foresees 2008 Omeprazole Launch; New Products Offset Sales Woes

This article was originally published in The Tan Sheet

Executive Summary

Perrigo expects to be able to launch the first store-brand equivalent to Prilosec OTC in November 2008, at the expiration of a 30-month stay

You may also be interested in...



Perrigo Hopes To Retain Lead From Leiner Woes, Eyes Private Label Zyrtec

Prompted by the sudden voluntary suspension of Leiner Health Product's U.S. OTC operations, private labeler Perrigo is looking to maintain its increased market share via key adjustments in its production processes to meet high customer demand

Perrigo Hopes To Retain Lead From Leiner Woes, Eyes Private Label Zyrtec

Prompted by the sudden voluntary suspension of Leiner Health Product's U.S. OTC operations, private labeler Perrigo is looking to maintain its increased market share via key adjustments in its production processes to meet high customer demand

Perrigo Hopes To Retain Lead From Leiner Woes, Eyes Private Label Zyrtec

Prompted by the sudden voluntary suspension of Leiner Health Product's U.S. OTC operations, private labeler Perrigo is looking to maintain its increased market share via key adjustments in its production processes to meet high customer demand

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100190

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel